Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy

After 20 years developing technology for slow-release injectable drugs, MedinCell of France has won its first FDA approval.

In combination with Teva, MedinCell has scored an FDA nod for Uzedy (risperidone), an extended-release injectable suspension treatment for adults with schizophrenia.